Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2000-09-21
2004-01-27
Swartz, Rodney P (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S947000, C429S184000, C429S200000, C429S200000
Reexamination Certificate
active
06682900
ABSTRACT:
BACKGROUND OF THE INVENTION
Chagas' disease is characterized by a short-term acute phase, with very few clinical symptoms, and a long-term chronic phase, usually accompanied by severe gastrointestinal and/or cardic complications which result in permanent physical disability or death.
Chagas' disease is an endemic disease caused by the flagellate
Trypanosoma cruzi
. In Latin America, approximately 16 to 18 million individuals are already infected and as many as 90 million individuals are at risk of infection (W.H.O., 1991). The disease is transmitted in Nature by Triatominae vectors. As a result of effective public health measures for the control of the vector in most countries. blood transfusion is quantitatively the most important form of transmission of the disease today. In Latin America, blood samples with antibodies associated with Chagas' disease represent 1-4% of the total blood samples in major Hemocenters. More recently, Chagas' disease has also become a major public health concern in North America, owing to the increasing number of immigrants from Latin American countries, in the last decade. Recent studies estimate that there may be in the United States approximately 100,000
Trypanosoma cruzi
-infected individuals with potential risk of transmitting Chagas' disease by blood transfusion (Hagar and Rahimtoola, 1991).
The diagnosis of acute Chagas' disease is not a problem because of the large number of parasites in the blood. In contrast, the chronic phase is diagnosed by serological methods because of the very small number or absence of circulating parasites. This has also restricted so far the use of polymerase chain reaction (PCR) with specific primers, as the final diagnostic test of Chagas' disease, before a major epidemiologic survey of sera from chronic patients is carried out.
The three serological methods that are currently being used in blood banks—indirect hemmagglutination (IHA), indirect immunofluorescence (IIF), and enzyme-linked immunosorbent assay (ELISA)—utilize mixtures of antigens prepared from the epimastigote form of the parasite. According to the World Health Organization (WHO), at least two positive tests of the three cited above are necessary for the diagnosis of the disease. Blood samples that are positive to only one of the three tests are classified as “indeterminate or inconclusive” and, in consequence, discarded. The indeterminate diagnosis is associated with 20 to 90% of all blood samples that gave one or more positive tests for Chagas' disease, depending on the methods employed and how they are applied. This high percentage of indeterminate results represents a serious problem in blood banks, both in terms of volume of discarded blood and doubtful diagnosis of Chagas' disease. In fact, a blood sample with a false positive test is no longer used for transfusion or isolation of cells and other blood components. Such loss of donated blood also affects the production of blood derivatives such as albumin, immunoglobulins and clotting factors which are of commercial value. Conversely, a blood sample with a false negative test is a dangerous source of contamination by the parasite.
The disadvantages of the current serological methods can be summarized as follows:
1. Low sensitivity: current methods use human sera at low dilutions, with a consequent increase in the background due to the cross-reactivity with natural antibodies and low-titer antibodies resulting from nonspecific polyclonal activation. Specific recombinant or synthetic epimastigote antigens, singly or in mixtures, are not sufficiently sensitive because they react only with a limited number of specific antibodies present in the sera of chronic Chagasic patient.
2. Low specificity: serological tests using epimastigote extracts cross-react with antigens from microbial sources other than
Trypanosoma cruzi
, notably Leishmania and some fungal and bacterial antigens.
BRIEF SUMMARY OF INVENTION
The invention describes the purification of the A&T and EpEx antigens, and their use in a chemiluminescent enzyme-linked immunosorbent assay (CL-ELISA), for the accurate diagnosis of Chagas' disease. When carried out in parallel, the results of the tests taken together provide high sensitivity and high specificity not obtainable with conventional methods described in the literature and/or which are commercially available.
REFERENCES:
patent: 3993743 (1976-11-01), Hanson
patent: 4870006 (1989-09-01), Dragon et al.
patent: 5234822 (1993-08-01), Pereira et al.
patent: 9400950-3 (1995-07-01), None
patent: WO 92/09895 (1992-06-01), None
patent: WO 97/05468 (1997-02-01), None
Almeida, I.C. et al. “A highly sensitive and specific chemiluminescent enzyme-linked immunosorbent assay for diagnosis of activeTrypanosoma cruzi infection”, Tranfusion, vol. 37, pp. 850-857, 1997.*
Grijalva,M.J. et al. “Blood donors in a vector-free zone of Ecuadopr potentially infected withTrypanosoma cruzi”. American Journal of Tropical Medicine and Hygiene, vol. 52, No. 4, pp. 360-363, 1995.*
Almeida, I.C. et al. “Lytic anti-alpha-galactolsyl antibodies from patients with chronic Chagas'disease . . . ” Biochemical Journal, vol. 304, pp. 793-802, 1994.*
Bates et al. , “Leishmania mexicana: Induction of Metacyclogensis by cCultivation”, Experimental Parasitology vol. 76, pp.412-423, 1993.*
Almeida, I.C. et al. “A highly sensitive and specific chemiluminescent enzyme-linked immunosorbent assay for diagnosis of activeTrypanosoma cruziinfection”, Tranfusion, vol. 37, pp. 850-857, 1997.*
Grijalva,M.J. et al. “Blood donors in a vector-free zone of Ecuadopr potentially infected withTrypanosoma cruzi”. American Journal of Tropical Medicine and Hygiene, vol. 52, No. 4, pp. 360-363, 1995.*
Almeida, I.C. et al. “Lytic anti-alpha-galactolsyl antibodies from patients with chronic Chagas'disease . . . ” Biochemical Journal, vol. 304, pp. 793-802, 1994.*
Biological Abstracts, XP00203817, vol. 97 (1997).
Almeida Igor C.
Covas Dimas Tadeu
Travassos Luiz R. R. G.
Fundação Hemocentro de Ribeirão Preto
Shahnan-Shah Khatol S.
Swartz Rodney P
LandOfFree
Serological diagnosis of Chagas' disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Serological diagnosis of Chagas' disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Serological diagnosis of Chagas' disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3231822